To determine whether the cell toxicity observed in lung cancer cells harboring ABL1 mutations can be attributed to inhibition of this kinase, we treated H1915 cells with ABL inhibitors and re‐expressed the drug‐resistant ABL1‐T315I mutant (Bixby & Talpaz, 2009). The gene discussed is ABL1; the disease is lung cancer.